1. 1362PSafety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene. (18th September 2017) Authors: Takeda, M.; Seto, T.; Fujiwara, Y.; Yamamoto, N.; Nosaki, K.; Toyozawa, R.; Abe, C.; Shiga, R.; Nakamaru, K.; Nakagawa, K. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0469 Patient-Oriented Decision of Early Treatment of Rheumatoid Arthritis with Combination of Triple Conventional Disease Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor Inhibitors and Methotrexate (Prospective, Open-Label Clinical Trial). (10th June 2014) Authors: Okada, M.; Matsuno, H.; Abe, C.; Katayama, K.; Kondo, M.; Sagawa, A.; Yamasaki, K.; Kishimoto, M.; Matsubara, T. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0248 Patient-Oriented Decision of Early Treatment of Rheumatoid Arthritis with Combination of Triple Conventional Disease Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor Inhibitors and Methotrexate (Prospective, Open-Label Clinical Trial). (23rd January 2014) Authors: Okada, M.; Matsuno, H.; Abe, C.; Katayama, K.; Kondo, M.; Sagawa, A.; Yamasaki, K.; Kishimoto, M.; Matsubara, T. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗